Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GP01CR11
- Development stage
- Preclinical
- Lead developer
- Exicure
- Modality
- Small Molecules
01
Overview
GP01CR11 is a preclinical-stage small molecule therapeutic being developed by GPCR Therapeutics. It is designed to target the C-X-C chemokine receptor type 4 (CXCR4) in conjunction with an undisclosed G protein-coupled receptor (GPCR). The drug is part of GPCR Therapeutics' focus on targeting GPCR heteromers, which are complexes formed by two different GPCRs that can drive disease progression more aggressively than individual receptors. By simultaneously modulating CXCR4 and its partner GPCR, GP01CR11 aims to disrupt signaling pathways involved in cancer cell proliferation, survival, and metastasis, particularly in the context of the tumor microenvironment.
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on GP01CR11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GP01CR11.